ArticleBlood cancer journal2026

Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety.

Atharva Karulkar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.